Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) and Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
Risk and Volatility
Alaunos Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.73, indicating that its share price is 173% less volatile than the S&P 500.
Earnings and Valuation
This table compares Alaunos Therapeutics and Telomir Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alaunos Therapeutics | $5,000.00 | 1,241.32 | -$4.18 million | ($2.21) | -1.18 |
| Telomir Pharmaceuticals | N/A | N/A | -$10.41 million | ($0.33) | -4.24 |
Alaunos Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
27.7% of Alaunos Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Alaunos Therapeutics and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -172.65% | -123.32% |
| Telomir Pharmaceuticals | N/A | -315.26% | -259.29% |
Analyst Recommendations
This is a summary of current recommendations for Alaunos Therapeutics and Telomir Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Telomir Pharmaceuticals | 1 | 1 | 1 | 0 | 2.00 |
Summary
Alaunos Therapeutics beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
